ALDX
$7.43
Aldeyra Therapeu
$.32
4.50%
ALDX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.28)
Revenue:  $0.00 Mil
Thursday
Nov 5
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALDX reports earnings?
Beat
Meet
Miss

Where is ALDX's stock price going from here?
Up
Flat
Down
Stock chart of ALDX
Analysts
Summary of analysts' recommendations for ALDX
Score
Grade
Pivots
Resistance
$8.05
$7.77
$7.60

$7.32

Support
$7.15
$6.87
$6.70
Tweet
Growth
Description
Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
Peers
InterCeptRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonZoetisUltragenyx PharmaceuticalBristol-Myers SquibbCatalentMerck & Co.